These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 21524390

  • 21. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K, Mountford WK, Hoffmann GF, Ries M.
    Orphanet J Rare Dis; 2015 Apr 18; 10():46. PubMed ID: 25896727
    [Abstract] [Full Text] [Related]

  • 22. Orphan drug regulations. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2013 Jun 12; 78(113):35117-35. PubMed ID: 23767079
    [Abstract] [Full Text] [Related]

  • 23. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec 12; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 24. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I, Breckenridge A.
    Clin Pharmacol Ther; 2012 Aug 12; 92(2):151-3. PubMed ID: 22814659
    [Abstract] [Full Text] [Related]

  • 25. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR.
    Pediatrics; 2010 Jul 12; 126(1):101-6. PubMed ID: 20566615
    [Abstract] [Full Text] [Related]

  • 26. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M, Kubácková K, Palágyi M, Smíd M.
    Cas Lek Cesk; 2006 Jul 12; 145(4):296-300. PubMed ID: 16639930
    [Abstract] [Full Text] [Related]

  • 27. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL.
    Drug Discov Today; 2009 Dec 12; 14(23-24):1166-73. PubMed ID: 19818412
    [Abstract] [Full Text] [Related]

  • 28. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2007 Dec 12; 20(1):45-55. PubMed ID: 17332899
    [Abstract] [Full Text] [Related]

  • 29. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K, Coté TR.
    Brief Bioinform; 2011 Jul 12; 12(4):341-5. PubMed ID: 21357612
    [Abstract] [Full Text] [Related]

  • 30. Orphan drug development in the United States.
    Groft SC.
    CPJ; 1985 May 12; 118(5):219-22. PubMed ID: 10271306
    [Abstract] [Full Text] [Related]

  • 31. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D, Thorat C, Phillips I, Thomas M, Imoisili MA.
    Drug Discov Today; 2012 Feb 12; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract] [Full Text] [Related]

  • 32. Two decades of orphan product development.
    Haffner ME, Whitley J, Moses M.
    Nat Rev Drug Discov; 2002 Oct 12; 1(10):821-5. PubMed ID: 12360259
    [Abstract] [Full Text] [Related]

  • 33. Orphanage at the FDA.
    Chen E.
    J Cardiovasc Transl Res; 2012 Oct 12; 5(5):735-6. PubMed ID: 21080134
    [No Abstract] [Full Text] [Related]

  • 34. [Orphan drugs--medications for patients with rare diseases].
    Thielke D, Thyssen JP, Hansen BJ.
    Ugeskr Laeger; 2006 Jun 05; 168(23):2236-8. PubMed ID: 16768975
    [Abstract] [Full Text] [Related]

  • 35. [Orphan drugs: drugs for rare diseases].
    Schenk M.
    Dtsch Med Wochenschr; 2010 May 05; 135(18):p17. PubMed ID: 20455291
    [No Abstract] [Full Text] [Related]

  • 36. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 37. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W, Denier Y, Dooms M, Cassiman JJ, Dierickx K.
    J Med Ethics; 2012 Mar 19; 38(3):148-53. PubMed ID: 21947805
    [Abstract] [Full Text] [Related]

  • 38. A regulatory overview about rare diseases.
    Llinares J.
    Adv Exp Med Biol; 2010 Mar 19; 686():193-207. PubMed ID: 20824447
    [Abstract] [Full Text] [Related]

  • 39. Orphan drugs: the regulatory environment.
    Franco P.
    Drug Discov Today; 2013 Feb 19; 18(3-4):163-72. PubMed ID: 22981668
    [Abstract] [Full Text] [Related]

  • 40. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ.
    Clin Ther; 2010 Aug 19; 32(9):1651-61. PubMed ID: 20974323
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.